Crossject annonce son éligibilité au dispositif d’investissement PEA-PME
September 26, 2024 01:30 ET
|
CROSSJECT
Le PEA-PME permet aux investisseurs particuliers français d'acheter des titres à des conditions fiscales préférentielles. Dijon, Sept 26, 2024 -- Crossject (ISIN : FR0011716265 ; Euronext : ALCJ),...
Crossject announces its eligibility for France’s PEA-PME investment scheme
September 26, 2024 01:30 ET
|
CROSSJECT
Enables French retail investors to buy securities under preferential tax conditions Dijon, France Sept 26, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company...
Epilepsy Foundation Introduces New Mission & Vision Statements at National Leadership Conference
September 23, 2024 08:00 ET
|
Epilepsy Foundation
After more than 50 years of operating under the same mission statement, the Epilepsy Foundation unveiled its new mission to staff, partners, and supporters
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
September 10, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
Tony Tipton nommé au poste de directeur des opérations États-Unis de Crossject en vue de la commercialisation de ZEPIZURE®, traitement d'urgence dans la prise en charge des crises d’épilepsie
August 19, 2024 11:30 ET
|
CROSSJECT
Communiqué de presse Tony Tipton nommé au poste de directeur des opérations États-Unis de Crossject en vue de la commercialisation de ZEPIZURE®, traitement d'urgence dans la prise en charge des...
Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment
August 19, 2024 11:30 ET
|
CROSSJECT
Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 13, 2024 07:00 ET
|
Praxis Precision Medicines, Inc.
Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of...
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
August 08, 2024 07:00 ET
|
Rapport Therapeutics, Inc.
Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
August 07, 2024 16:11 ET
|
Catalyst Pharmaceuticals, Inc.
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million,...
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
July 25, 2024 05:00 ET
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...